SAN FRANCISCO — Illumina will not be the only array vendor submitting a cytogenetics-focused array to the US Food and Drug Administration for clearance this quarter. Affymetrix CEO Frank Witney told investors at the JP Morgan Global Healthcare Conference here this week that the company is on track to submit its CytoScan array to the agency in Q1.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.